Mvasi and Death - a phase IV clinical study of FDA data

Summary:

Death is reported as a side effect among people who take Mvasi (bevacizumab-awwb), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Lonsurf, and have Colon cancer.

The study is created by eHealthMe based on reports of 3,295 people who have side effects when taking Mvasi from the FDA, and is updated regularly.

What is Mvasi?

Mvasi has active ingredients of bevacizumab-awwb. eHealthMe is studying from 3,295 Mvasi users. Check the latest studies of Mvasi.

On Jul, 16, 2026

3,295 people reported to have side effects when taking Mvasi.
Among them, 46 people (1.4%) died.

Among these 46 people:

How long have people been on Mvasi when they died? *

What is the gender of people who died when taking Mvasi? *

female: 45.95 %
male: 54.05 %

What is the age of people who died when taking Mvasi? *

What are other drugs people take besides Mvasi? *

What are other side effects people have before they died? *

Disease Progression: 5 people, 10.87%
Hospitalisation: 3 people, 6.52%
Adverse Drug Reaction: 3 people, 6.52%
Fatigue (feeling of tiredness): 3 people, 6.52%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 3 people, 6.52%
High Blood Pressure: 3 people, 6.52%
Cerebral Haemorrhage (bleeding within the brain): 2 people, 4.35%
Nausea And Vomiting: 2 people, 4.35%
Nosebleed (bleeding from nose): 2 people, 4.35%
Pneumonia: 2 people, 4.35%

What are the existing conditions these people have? *

Colon Cancer: 9 people, 19.57%
Hepatocellular Carcinoma (liver cancer): 5 people, 10.87%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 4 people, 8.70%
Rectal Cancer (cancer of rectum): 3 people, 6.52%
Ovarian Cancer (cancer of ovary): 3 people, 6.52%
Glioblastoma (most common and most aggressive malignant primary brain tumour in humans): 3 people, 6.52%
Neoplasm Malignant (cancer tumour): 2 people, 4.35%
Metastases To Liver (cancer spreads to liver): 2 people, 4.35%
Lung Cancer - Non-Small Cell (lung cancer): 2 people, 4.35%
Hypersensitivity: 2 people, 4.35%

* Approximation only. Some reports may have incomplete information.

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mvasi:

Mvasi (3,295 reports)

Expand to all the drugs that have ingredients of bevacizumab-awwb:

Death and drugs with ingredients of bevacizumab-awwb

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Mvasi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Death:

Death (3,126 drugs)

Browse all the conditions that are associated with Death:

Death (3,686 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on bevacizumab-awwb (the active ingredients of Mvasi) and Mvasi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.